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background: More than half of pregnantwomen in theWesternworld report intakeofmild analgesics, and someof these drugs have been
associated with anti-androgenic effects in animal experiments. Intrauterine exposure to anti-androgens is suspected to contribute to the recent
increase in male reproductive problems, and many of the anti-androgenic compounds are like the mild analgesics potent inhibitors
of prostaglandin synthesis. Therefore, it appears imperative to further investigate the potential endocrine disrupting properties ofmild analgesics.
methods: In a prospective birth cohort study, 2297 Danish and Finnish pregnant women completed a questionnaire and 491 of the Danish
mothers participated in a telephone interview, reporting on their use ofmild analgesics during pregnancy. The testicular position of newbornswas
assessed by trained paediatricians. In rats, the impact of mild analgesics on anogenital distance (AGD) after intrauterine exposure was examined
together with the effect on ex vivo gestational day 14.5 testes.
results: In theDanish birth cohort, the use ofmild analgesics was dose-dependently associatedwith congenital cryptorchidism. In particular,
use during the second trimester increased the risk. This risk was further increased after the simultaneous use of different analgesics. The associ-
ation was not found in the Finnish birth cohort. Intrauterine exposure of rats to paracetamol led to a reduction in the AGD and mild analgesics
accordingly reduced testosterone production in ex vivo fetal rat testes.
conclusion: There was an association between the timing and the duration of mild analgesic use during pregnancy and the risk of cryp-
torchidism. These ﬁndings were supported by anti-androgenic effects in rat models leading to impaired masculinization. Our results suggest that
intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders.
Key words: testosterone / andrology / animal model / environmental effects / testis
Introduction
Paracetamol (acetaminophen) and non-steroidal anti-inﬂammatory
drugs (NSAIDs) acetylsalicylic acid (aspirin) and ibuprofen are widely
used mild analgesics. In both Europe and the USA, more than 50%
of pregnant women report intake of mild analgesics with the majority
using paracetamol (Werler et al., 2005; Rebordosa et al., 2008b).
Studies from the 1980s have suggested a link between prenatal
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exposure to mild analgesics and reduced masculinization in animals
(Gupta and Goldman, 1986; Gupta, 1989). This is of concern, since
several reports have indicated an increase in the incidence of male
reproductive disorders over the recent decades (Swan et al., 1997;
Boisen et al., 2004, 2005; Richiardi et al., 2004) and the geographical
distribution together with migration studies (Hemminki and Li, 2002)
have suggested that lifestyle and environmental factors play key roles in
the pathogenesis.
Reproductive disorders such as congenital cryptorchidism, hypospa-
dias, poor semen quality and testicular cancer have been hypothesized
to constitute a testicular dysgenesis syndrome (TDS) of fetal origin
due to interference in testis development (dysgenesis) (Skakkebaek
et al., 2001). Accordingly, data from rat studies have indicated that
androgen deﬁciency during a critical male programming window from
gestational day (GD) 15.5–17.5 (corresponding to 8–14 weeks of ges-
tation in humans) leads to cryptorchidism, hypospadias, compromised
fertility and reduction in anogenital distance (AGD; Welsh et al.,
2008). However, the agent(s) leading to androgen insufﬁciency and
their point of endocrine disruption have remained elusive. We have
recently found that many of the endocrine disrupting compounds that
reduce masculinization in animal studies by interfering with Leydig cell
function and differentiation are potent inhibitors of prostaglandin (PG)
synthesis (D. M. Kristensen et al., submitted for publication). This
could suggest that these endocrine disrupting compounds damage
male reproductive function by inhibiting PG synthesis. This hypothesis
is supported by the previous indications that mild analgesics, which
relieve pain and reduce inﬂammation by reducing PG synthesis, may
reduce testosterone production (Gupta and Goldman, 1986; Gupta,
1989). If so, pharmaceutical PG inhibitors, at the doses used by
humans, could act as endocrine disruptors. In this study, we investigated
whether mild analgesics have effects that manifest as male reproductive
disorders using a human prospective birth cohort and experimental
animal models (Fig. 1).
Materials and Methods
Design of the human study
The prospective birth cohort study was conducted at the University Hos-
pital of Copenhagen (Rigshospitalet and Hvidovre Hospital) in Denmark
and the Turku University Central Hospital in Finland as described pre-
viously (Boisen et al., 2004). Researchers from both countries closely col-
laborated in study design and recruitment, and examinations were
completely standardized. To keep inter-observer variation to a
minimum, bi-national workshops were held regularly and borderline
cases were examined by two researchers from the national study
groups. The study was done according to the Helsinki Declaration and
Figure 1 Schematic representation of the three segments of the study. (i) A prospective human study where pregnant women in the third trimester
were speciﬁcally asked about their use of mild analgesics. Shortly after birth testicular position was examined by trained paediatricians; (ii) an in vivo/
intrauterine study where pregnant rat dams were exposed to the mild analgesics from GD13 to 21 followed by measurement of the fetuses’ AGD and
testosterone production; (iii) an ex vivo study where testis from male rat fetuses were incubated for 3 days in media with or without the test com-
pounds. The media concentration of PGD2 and testosterone were measured after 24, 48 and 72 h.
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was approved by the local Danish and Finnish ethics committees and the
Danish Data Protection Agency. Written informed consent was given by
all parents.
Eligible women resident in hospital referral areas were recruited con-
secutively during pregnancy. To obtain genetically well-deﬁned popu-
lations, only families who met the following criteria were included: both
parents and grandparents of the unborn child should have been born
and raised in Denmark or Finland with a maximum residence abroad of
3 years for the mother and 10 years for the father and grandparents.
Gestational age was based on routine ultrasonographical ﬁndings in preg-
nancy week 18–20, if available. In the remaining cases, the last menstrual
period was used. Birthweight was obtained from birth records. The exam-
ination technique and the deﬁnition of cryptorchidism developed by Scorer
(1964) were applied. The testis was deﬁned as cryptorchid if it was found
high scrotal, supra-scrotal, inguinal or non-palpable after clinical examin-
ation by trained paediatricians.
In the Danish cohort, 2521 (22% of all eligible) mothers entered the
study and 1071 boys were examined at birth. A total of 5 boys were
excluded as dependent cases and 26 were excluded due to missing
data. The mothers of the 1040 resulting boys participated in a self-admi-
nistered written questionnaire in the third trimester (834 boys) or in a
computer assisted telephone interview in the third trimester as part of
the Danish National Birth Cohort (491 boys) (Olsen et al., 2001), answer-
ing questions concerning disease and medicine use during the pregnancy.
Mothers of 285 boys participated in both the telephone interview and
the questionnaire.
In Finland, 2728 families (24% of all eligible) entered the study and a
total of 1499 boys were examined at birth. Of these, 25 boys were
excluded as dependent cases as an older brother had already been
included in the study and 4 were excluded due to missing data. Of the
resulting 1470 boys, 1463 had mothers who participated in a self-
administered written questionnaire during the third trimester, answering
questions concerning disease and medicine use during the pregnancy.
The written questionnaire in both countries assessed medication in
general (‘Have you taken any medication during this pregnancy’), its indi-
cation, name, dosage and gestational week of administration, whereas
the computer-assisted telephone interview performed only in Denmark
speciﬁcally addressed the use of analgesics (‘Have you taken any pain-relief
medicine during this pregnancy, e.g. normal painkillers or stronger
brands?’). If ‘yes’, mothers were asked to specify the product and gesta-
tional weeks of use.
Animal models
All animal experiments were approved by the local Danish and French
ethics committees. Paracetamol and acetylsalicylic acid used in animal
experiments were purchased from Sigma-Aldrich (St Louis, MO, USA).
Animal intrauterine studies were conducted after the standardized pro-
cedure for detection of anti-androgenic compounds using AGD as readout
for the fetal testosterone level and hence masculinization as described pre-
viously (Vinggaard et al., 2005). Compounds were administered by gavage
from GD13 to 21 and Caesarean section at GD21 using Wistar rats. Para-
cetamol was administrated in subtoxic doses of 150, 250 and 350 mg/kg/
day (Ghanem et al., 2009), whereas acetylsalicylic acid was administered in
doses of 150, 200 and 250 mg/kg/day with a lower top dose due to its
known adverse effect on pregnancies (Gupta et al., 2003). For dose–
response analysis, AGD data were analysed by the calculated AGD
index (AGDi), deﬁned as AGD divided by the cube root of the body
weight (Gallavan et al., 1999). Analysis of testosterone and testosterone
production in GD21 fetal testes were performed as described previously
(Vinggaard et al., 2005).
An ex vivo organotypic culture system was used to examined exposure
effects at the time of fetal testosterone production initiation at GD14.5.
The culture system supports normal differentiation of the Sprague–
Dawley rat testes for 3 days (Habert et al., 1991) and has been validated
for toxicological studies (Lassurguere et al., 2003; Chauvigne et al., 2009).
The experiments were performed as described previously (Chauvigne
et al., 2009), however, with two testes in each experiment to increase
the amount of secreted PGD2 and testosterone. PGD2 and testosterone
were measured with Prostaglandin D2-Mox EIA kit (Cayman Chemicals,
Ann Arbor, MI, USA) and Coat-A-Count Total Testosterone (Siemens,
Los Angeles, CA, USA), respectively.
Statistics
Statistical analysis of the human data was performed using SPSS 16.0
(Chicago, IL, USA). Differences between the groups were tested with
Fisher’s exact test. We calculated odds ratios (ORs, 95%) by logistic
regression, and the model was adjusted for disease reported during preg-
nancy (indication to treat), use of other medications during pregnancy,
gestational age and twins (only written questionnaires), whereas no con-
founding effects was observed with birthweight, twins (only the telephone
interview), mother’s age, smoking, chronic disease and infectious disease.
Animal data were analysed using GraphPad Prism version 4 (La Jolla,
CA, USA) and SAS (Cary, NC, USA). Values are expressed as the
mean+ SEM. Data from rat intrauterine exposure experiments were ana-
lysed using analysis of variance (ANOVA) followed by Dunnett’s post hoc
test with litter as the statistical unit and included as a random factor in a
mixed model. Data for fetal rat testes culture experiments were analysed
using a two-sided unpaired Student’s t-test.
Results
Prospective birth cohort study
In the self-administrated questionnaire, 26.1% (218 of 834) of Danish
mothers reported the use of mild analgesics as opposed to 56.2% (276
of 491) in the computer-assisted telephone interview. Among the 285
Danish mothers who completed both, 30.9% (88 of 285) reported use
in the questionnaire as opposed to 57.2% (163 of 285) in the computer-
assisted telephone interview. These ﬁndings indicated that manymothers
did not consider mild analgesics as medication and hence strongly under-
reported their use unless speciﬁcally asked. We therefore only included
the data from the computer-assisted telephone interview from the
Danish part of the study (for Danish questionnaire results, see Sup-
plementary data, Tables SI and SII). Reasons for using mild analgesics
were headache in 66.5%, muscle ache in 6.4% and other types of pain
accounted for 8.7%. Fever, inﬂammation and inﬂuenza/cold accounted
for 6.9% and several of before mentioned reasons for 6.9%. Other
reasons and no reason accounted for the ﬁnal 4.6%.
Of the mothers with cryptorchid sons, 64.3% (27 of 42) reported
the use of mild analgesic during pregnancy versus 55.5% (249 of
449) of mothers with healthy boys [adjusted OR 1.43 (0.73–2.79),
P ¼ 0.33; Table I]. The higher prevalence of cryptorchidism became
signiﬁcant for mothers reporting use of more than one speciﬁc analge-
sic [adjusted OR 7.55 (1.94-29.3), P ¼ 0.007].
Use during the second trimester in particular increased the risk
of congenital cryptorchidism [adjusted OR 2.3 (1.12–4.73), P ¼
0.032]. The risk remained signiﬁcant for the individual compounds ibu-
profen and acetylsalicylic acid and showed the same trend for paraceta-
mol. The risk was further increased among mothers who reported the
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Table I Maternal use of mild analgesics during pregnancy in relation to congenital cryptorchidism.
Prevalence (%) Cryptorchidisma
[n (%)]
Normal
[n (%)]
Fisher’s exact (P) OR crude
(95% CI)
OR adjusted
(95% CI)b
Nc
Denmark
Use of mild analgesics during pregnancy
No 7.0 15 (35.7) 200 (44.5) 0.33 1.45 (0.75–2.79) 1.43 (0.73–2.79) 491
Yes 9.8 27 (64.3) 249 (55.5)
Use of speciﬁc compounds during pregnancy
Paracetamol
No 7.4 19 (45.2) 238 (53.1) 0.34 1.37 (0.73–2.59) 1.337 (0.70–2.55) 490
Yes 9.9 23 (54.8) 210 (46.9)
Acetylsalicylic acid
No 8.0 36 (85.7) 416 (92.9) 0.12 2.17 (0.85–5.53) 2.22 (0.86–5.76) 490
Yes 15.8 6 (14.3) 32 (7.1)
Ibuprofen
No 8.3 39 (92.9) 430 (96) 0.411 1.84 (0.52–6.51) 1.82 (0.5–6.61) 490
Yes 14.0 3 (7.1) 18 (4)
Simultaneous use of .1 compound
No 7.9 38 (90.5) 440 (98.5) 0.007 7.72 (2.09–28.6) 7.55 (1.94–29.3) 488
Yes 40 4 (9.5) 6 (1.3)
Use of mild analgesics during ﬁrst trimester
No 8.5 26 (74.3) 280 (80.0) 0.39 1.39 (0.62–3.09) 1.48 (0.66–3.34) 385
Yes 11.4 9 (25.7) 70 (20.0)
Use of speciﬁc compounds during ﬁrst trimester
Paracetamol
No 8.5 29 (80.6) 313 (86.5) 0.319 1.54 (0.64–3.71) 1.61 (0.66–3.90) 398
Yes 12.5 7 (19.4) 49 (13.5)
Acetylsalicylic acid
No 8.0 37 (90.2) 423 (96.8) 0.059 3.27 (1.02–10.4) 5.60 (1.83–17.1) 478
Yes 22.2 4 (9.8) 14 (3.2)
Ibuprofen
No 8.8 42 (100) 434 (97.7) – – – 486
Yes 0.0 0 (0) 10 (2.3)
Simultaneous use of .1 compound
No 8.3 40 (95.2) 442 (99.1) 0.087 5.53 (0.89–31.1) 5.63 (0.98–32.4) 488
Yes 33.3 2 (4.8) 4 (0.9)
Use of mild analgesics during second trimester
No 7 19 (54.3) 253 (72.3) 0.032 2.20 (1.09–4.45) 2.30 (1.12–4.73) 385
Yes 14.2 16 (45.7) 97 (27.7)
Use of speciﬁc compounds during second trimester
Paracetamol
No 7.6 23 (63.9) 280 (77.3) 0.099 1.93 (0.94–3.98) 1.97 (0.94–4.12) 398
Yes 13.7 13 (36.1) 82 (22.7)
Acetylsalicylic acid
No 7.8 36 (87.8) 425 (97.3) 0.01 4.92 (1.64–14.7) 3.76 (1.15–12.3) 478
Yes 29.4 5 (12.2) 12 (2.7)
Ibuprofen
No 8.2 39 (92.9) 437 (98.4) 0.047 4.8 (1.19–19.3) 4.59 (1.1–19) 486
Yes 30.0 3 (7.1) 7 (1.6)
Continued
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simultaneous use of more than one analgesic [adjusted OR 16.1 (3.29–
78.6), P ¼ 0.001]. Separating the cases with cryptorchidism into high
scrotal and more severe forms showed an increased risk in both cat-
egories after the maternal use of mild analgesics (Fig. 2).
To test whether the risk of cryptorchidism was associated with the
extent of analgesic use, we categorized the mothers into three groups,
consisting of (i) no use, (ii) use for 1–2 weeks and (iii) use for more
than 2 weeks during ﬁrst and second trimester. Mothers who reported
intake of mild analgesics for more than 2 weeks had a signiﬁcantly
increased risk of giving birth to boys born with cryptorchidism
[adjusted OR 2.47 (1.02–5.96), P ¼ 0.045], with similar individual
results for paracetamol and acetylsalicylic acid (Fig. 2 and Table II).
The highest risk was observed among the small number of mothers
who used more than one compound simultaneously for more than
2 weeks [adjusted OR 21.7 (1.83–258), P ¼ 0.015].
Despite underreporting, results from the Danish written question-
naire showed a trend in the same direction (Supplementary data,
Tables SI and SII). However, based on the questionnaire data, the use
of analgesic medicinewas in general not associatedwith congenital cryp-
torchidism in the Finnish cohort, except for a trend in the second trime-
ster (Tables I and II). We did not ﬁnd a signiﬁcant association between
the use of mild analgesics and hypospadia in the two birth cohorts.
Intrauterine rat model
To verify the association seen in the prospective birth cohort between
mild analgesics and the altered testis descent, we extended the inves-
tigation with the use of intrauterine exposure experiments in the rat
with AGD as end-point as this is a more sensitive marker for
reduced intrauterine androgen levels than cryptorchidism (Welsh
et al., 2008). No clinical signs of general toxicity were observed
during the daily observations. At GD21, the pregnant dams were
sacriﬁced and examined together with the fetuses. No signs of liver
toxicity were detected. Maternal body weight gain, litter sizes,
number of live fetuses, resorptions and implantation as well as the
sex ratio in the litters were not affected in the dosed groups when
compared with controls (Supplementary data, Table SIII).
Intrauterine exposure to paracetamol resulted in reduced AGDi in
male fetuses for all three dose groups (Fig. 3 and Supplementary data,
Table SIV). To ascertain these results, we performed an additional and
independent study with a larger group of animals, using only the top
dose of 350 mg/kg/day paracetamol. Consistent with the previous
data, this experiment showed a signiﬁcant reduction in AGDi in the
.............................................................................................................................................................................................
Table I Continued
Prevalence (%) Cryptorchidisma
[n (%)]
Normal
[n (%)]
Fisher’s exact (P) OR crude
(95% CI)
OR adjusted
(95% CI)b
Nc
Simultaneous use of .1 compound
No 7.9 38 (90.5) 443 (99.3) 0.001 15.5 (3.36 – 72) 16.1 (3.29–78.6) 488
Yes 57.4 4 (9.5) 3 (0.70)
Finland
Use of mild analgesics during pregnancy
No 2.6 22 (62.9) 822 (57.6) 0.61 0.80 (0.40–1.60) 0.74 (0.35–1.57) 1463
Yes 2.1 13 (37.1) 606 (42.4)
Use of mild analgesics during ﬁrst trimester
No 2.6 28 (84.8) 1057 (84.4) 1.00 0.96 (0.37–2.52) 0.77 (0.26–2.27) 1286
Yes 2.5 5 (15.2) 196 (15.6)
Use of mild analgesics during second trimester
No 2.4 24 (72.7) 972 (77.6) 0.53 1.30 (0.60–2.82) 1.21 (0.53–2.76) 1286
Yes 3.1 9 (27.3) 281 (22.4)
aTestis deﬁned as cryptorchid if it was high scrotal, supra-scrotal, inguinal and non-palpable.
bAdjusted for gestational age, reported disease and use of other medicine during pregnancy.
cThe numbers differ since not all women provided information about the trimester of use.
Figure 2 Mean prevalence of congenital cryptorchidism relative to
weeks of maternal use of any mild analgesics and paracetamol during
the ﬁrst and the second trimester. *P, 0.05. P-values are between
mothers using no compounds and analgesic use for .2 weeks and
are adjusted for disease, use of other medicine and gestational age
using logistic regression. Error bars are +1.96 SE.
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male fetuses. When the data from the two paracetamol studies were
combined, including study number as a factor in the statistical analysis,
the signiﬁcance of reductions in AGD and AGDi for all three dose
groups was further increased (data not shown). Furthermore, when
testosterone production by the fetal testes was assessed, we found
a non-signiﬁcant reduction for the highest doses in both experiments
compared with the unexposed control groups (Supplementary data,
Table SV).
We also performed an intrauterine exposure study with
acetylsalicylic acid, which resulted in shorter AGD in all male fetuses
compared with controls. However, as expected from previous exper-
iments (Gupta et al., 2003), acetylsalicylic acid also resulted in intrau-
terine fetal growth retardation to such a degree that the difference in
AGD was undetectable after adjusting for body weight (Supplemen-
tary data, Table SIV). Examination of testosterone production by the
testes exposed in utero to acetylsalicylic acid showed a signiﬁcant
(P, 0.05) and not signiﬁcant (P ¼ 0.065 and 0.077) reduction, com-
pared with unexposed control testes (Supplementary data, Table SV).
Ex vivo rat model
Since intrauterine androgens are required for normal abdominal trans-
location of the testes (Boisen et al., 2004; Tomiyama et al., 2005; Swan
et al., 2005; Scott et al., 2009) and decreased AGD is a indicator for
reduced intrauterine androgen levels (Welsh et al., 2008), we next
used organotypic culture of fetal rat testes to examine effect of mild
analgesics on fetal testosterone production. The ex vivo system sup-
ports normal differentiation of fetal rat gonads as reﬂected by the pro-
gressive increase in testosterone production and has been validated
for toxicological studies (Habert et al., 1991; Lassurguere et al.,
2003; Chauvigne et al., 2009). The increase in testosterone production
indicates that the number of Leydig cells continued to increase and/or
mature throughout the 3 days of culture during the masculinization
window (Chauvigne et al., 2009). The mild analgesics reduced
PGD2 production (Fig. 4A and 4C) and in the presence of 1 mM para-
cetamol secretion of testosterone were consistently reduced by
50% throughout the assay period (Fig. 4B). A similar dose-
dependent reduction in testosterone was seen with 10 mM acetylsa-
licylic acid at all time points with statistical signiﬁcance at a dose of
10 mM (Fig. 4D).
Discussion
In this comprehensive study, we found a direct association between
both the timing and extent of mild analgesic consumption during
.............................................................................................................................................................................................
Table II Extent of maternal use of mild analgesics in ﬁrst and second trimester of pregnancy in relation to congenital
cryptorchidism.
Compound Weeks of usage Na Cryptorchidism (%)b OR crude (95% CI) OR adjusted (95% CI)c
Denmark
Mild analgesics 0 236 7.2 1 1
1–2 87 10.3 1.49 (0.64–3.47) 1.5 (0.63–3.55)
.2 62 14.5 2.19 (0.92–5.18) 2.47 (1.02–5.96)
Paracetamol 0 278 7.6 1 1
1–2 74 9.5 1.28 (0.52–3.13) 1.26 (0.5–3.14)
.2 46 17.4 2.58 (1.07–6.23) 2.78 (1.13–6.84)
Acetylsalicylic acid 0 454 7.9 1 1
1–2 11 18.2 2.58 (0.54–12.4) 2.75 (0.56–13.5)
.2 13 23.1 3.35 (0.92–13.2) 4.07 (1.05–15.8)
Ibuprofen 0 470 8.3 1 1
1–2 11 27.3 4.14 (1.06–16.3) 3.85 (0.93–15.9)
.2 5 0 – –
Use of .1 compound 0 478 7.9 1 1
1–2 7 28.6 4.63 (0.87–24.7) 4.63 (0.83–52.8)
.2 3 66.7 23.16 (2.05–261) 21.69 (1.83–258)
Finland
Mild analgesics 0 905 2.5 1 1
1–2 231 3.0 1.20 (0.51–2.83) 1.21 (0.50–2.90)
.2 150 2.0 0.78 (0.23–2.64) 0.56 (0.13–2.45)
Paracetamol 0 945 2.5 1 1
1–2 214 2.8 1.11 (0.45–2.74) 1.01 (0.44–2.79)
.2 131 2.3 0.90 (0.27–3.03) 0.64 (0.15–2.79)
aThe numbers differ between the different mild analgesics since not all women provided information about duration of use.
bTestis deﬁned as cryptorchid if it was high scrotal, supra-scrotal, inguinal and non-palpable.
cAdjusted for gestational age, reported disease and use of other medicine during pregnancy.
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pregnancy and the risk of giving birth to a son with congenital cryp-
torchidism, the best described risk factor for poor semen quality
and testicular germ cell cancer (Boisen et al., 2004). Using two
different rat models, we further support these data and show that
fetal exposure to mild analgesics exerts an anti-androgenic action in
the male.
The cohort study was performed by trained paediatricians and
incorporated mild cryptorchidism (high scrotal testis) as part of the
continuum of maldescent, which is reﬂected in subtle primary testicu-
lar dysfunction (Suomi et al., 2006), setting this study signiﬁcantly apart
from former investigations that focused exclusively on the most severe
types of cryptorchidism reported in Hospital registries (Norgard et al.,
2005; Ofori et al., 2006; Rebordosa et al., 2008a). The results indicate
an increase in prevalence after the maternal use of mild analgesic in
both the mild and more severe forms of congenital cryptorchidism.
Importantly, data from mothers, who completed both a self-admini-
strated questionnaire and participated in a computer-assisted tele-
phone interview, revealed a pit fall in the questionnaire data since
many mothers had not considered mild analgesics as ‘true’ medication
and hence underreported their use. The majority of the mothers used
the analgesics due to simple pain such as headache and muscle ache,
consistent with the fact that adjusting for underlying diseases did not
change the association between the use of mild analgesics and cryp-
torchidism. This indicates that our observations do not result from
speciﬁc diseases, which encouraged the women to take analgesics.
The association with cryptorchidism was not found in the Finnish
cohort, except for a trend in the second trimester. However, the
birth prevalence of cryptorchidism in Finland (2.4%) was much
lower than that in Denmark (9.0%; Boisen et al., 2004) and our
study may be statistically underpowered to ﬁnd an association. In
accordance, the association we ﬁnd in the Danish cohort was recently
Figure 3 Intrauterine exposure from GD13 to 21 to paracetamol
in rats led to a reduction in the testosterone-dependent AGD of
male offspring. Results from initial experiment performed with four
to ﬁve litters per dose group and the verifying experiment (+) per-
formed with six litters per dose group. ***P, 0.001, **P, 0.01,
*P, 0.05. P-values are from ANOVA followed by Dunnett’s post
hoc test with litter as the statistical unit and included as a random
factor in a mixed model. There is no signiﬁcant difference between
treated groups. Data represent the mean+ SEM.
Figure 4 Mild analgesic compounds paracetamol and acetylsalicylic acid reduced PGD2 and testosterone production in ex vivo cultured GD14.5 rat
testes. (A) Paracetamol (n ¼ 10) and (C) acetylsalicylic acid (n ¼ 8) reduced PGD2 secretion during ex vivo culture. (B) Paracetamol (n ¼ 10) and (D)
acetylsalicylic acid (n ¼ 13) reduced testosterone secretion from the fetal rat testes during 3 days of ex vivo culture. ***P, 0.001, **P, 0.01,
*P, 0.05. P-values are from a two-sided unpaired Student’s t-test. Data represent the mean+ SEM.
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supported by an independent Danish study of 47 400 boys with an
incidence of cryptorchidism (2%) similar to that observed in the
Finnish cohort (Jensen et al., 2010). In that study, they report a signiﬁ-
cant association between the use of paracetamol in weeks 8–14 and
cryptorchidism (Jensen et al., 2010). We did not ﬁnd an association
with hypospadia in any of the birth cohorts; however, the incidence
of hypospadia was very low at birth (1% in the Danish and 0.3% in
the Finnish cohort) and it is not clear how large the association is
between cryptorchidism and hypospadia (Akre and Richiardi, 2009;
Jørgensen et al., 2010).
It is widely accepted that androgens are required for normal abdominal
translocation of the testes (Boisen et al., 2004; Swan et al., 2005;
Tomiyama et al., 2005; Scott et al., 2009). Therefore, a particular strength
of this study is the use of two complementary rat models to support the
contention that the association between analgesic use and cryptorchidism
seen in our cohort study may result from a reduction in androgen pro-
duction. Intrauterine exposure to paracetamol, with a lowest dose of
150 mg/kg/day, resulted in a decrease in fetal testosterone-dependent
AGDi comparable with effects seen after exposure to known anti-
androgenic compounds such as phthalates (Borch et al., 2006), which
have PG inhibitory properties similar to those of mild analgesics (D. M.
Kristensen et al., submitted for publication). Since this is only three
times the dose recommended for humans of 50 mg/kg/day, further
work is needed to determined the no adverse effect level. Effects after
exposure to acetylsalicylic acid in the rats were more severe than after
paracetamol and resulted in fetal growth retardation, which is in line
with previous reports (Gupta et al., 2003), and reduction in testosterone
production as also described in mouse studies (Gupta and Goldman,
1986). Examination of mild analgesics’ effects directly on the initiation of
fetal testosterone production in GD14.5 rat testes further supported
the notion of a direct anti-androgenic effect. Surprisingly, paracetamol
was the most potent inhibitor of testosterone production and had signiﬁ-
cant inhibitory effect already at 1 mM, which is well below the therapeuti-
cally plasma concentration of 65–130 mM. Hence, there was no direct
correlation in this assay between the potency of the different mild analge-
sics on PG synthesis and the inhibition of testosterone. This is in contrast
to the human data, where ibuprofen, as the most potent PG synthesis
inhibitor, was associated with the highest risk of congenital cryptorchid-
ism. Acetylsalicylic acid has previously been shown to partially block the
increase in testosterone production after hCG stimulation of adult men
(Conte et al., 1999). A similar scenario is plausible during fetal develop-
ment, which could account for the anti-androgenic effect. Experiments
in rats have shown that decrease in androgen action during a speciﬁcmas-
culinizationprogrammingwindow, corresponding approximately to gesta-
tional week 8–14 in humans, results in an increase in male reproductive
disorders including cryptorchidism (Welsh et al., 2008). This corresponds
to the end of the ﬁrst and the start of the second trimester, which is in
accordance with the birth cohort study and supported by the study by
Jensen et al. (2010). However, since PGD2 plays a role in early male
sexual differentiation (Adams and McLaren, 2002; Wilhelm et al., 2007)
and the results show an inhibition of this paracrine factor in the fetal rat
testes, it is also possible that there are an additional effect on testes
development.
During the late 1950s, a Danish investigation similar to this study in
terms of design included 2700 boys born at Rigshospitalet, Copenha-
gen (Buemann et al., 1961). Comparing the prevalence of congenital
cryptorchidism with the data from the present cohort indicate a
marked increase in the incidence of this disorder (1.8% in 1959–
1961 versus 8.5% in 1997–2001, P, 0.001; Boisen et al., 2004).
The magnitude of this difference is too large to be accounted for by
random ﬂuctuations and differences in ascertainment. Moreover, this
ﬁnding is in accordance with the reported decline in reproductive
health in the adult male population over the past ﬁve decades
(Swan et al., 1997; Richiardi et al., 2004). The epidemiological and
clinical associations between reproductive health problems such as
subfertility, testicular germ cell cancer and cryptorchidism suggest
the existence of etiologic and pathogenic links, as suggested in the
TDS hypothesis (Skakkebaek et al., 2001). Observations made in wild-
life after environmental accidents have yielded substantial evidence of
adverse developmental effects caused by endocrine disrupters and
studies on phthalates in humans have shown that there is an associ-
ation between maternal exposure and reduction in AGD and cryp-
torchidism among newborn boys (Swan et al., 2005). Recent studies
also indicate that anti-androgens, which in low concentrations exert
no effects, when combined induce reproductive disorders (Hass
et al., 2007). Thus, since pregnant women in the Western world
are constantly and inevitably exposed to low concentrations of a
large number of different anti-androgens (Diamanti-Kandarakis et al.,
2009; Scott et al., 2009), of which many are PG synthesis inhibitors
(D. M. Kristensen et al., submitted for publication), consumption of
mild analgesics such as paracetamol could in combination with
exposure to environmental PG inhibitory and anti-androgenic com-
pounds be a contributing factor to the increased incidence of cryp-
torchidism and later life reproductive problems.
Collectively, the results points to a scenario where the use of mild
analgesic medicine has a possible effect on fetal development with
implications for later reproductive health. Therefore, more investi-
gations are urgently needed and we will for our part continue to
follow the boys in our cohorts, who currently are entering puberty.
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